Key Highlights

  • Core One Labs was Delisted from the Canadian Securities Exchange on September 19, 2025, leaving U.S. OTC trading as its main venue.
  • The company focuses on psychedelic medicine, including biosynthetic psilocybin production and delivery-technology platforms.
  • Trailing-twelve-month Revenue was only a few hundred thousand dollars against a net loss in the range of roughly $12 million.

A quoted price near one hundred-thousandth of a dollar tells most of the story about Core One Labs Inc, the Canadian psychedelics developer that trades in the United States under the ticker CLABF. What the uploaded snapshot labels a stock holding "steady" is, on closer inspection, a security that has lost essentially all of its Market Value and now sits at the very bottom of the over-the-counter market. For CLABF, the relevant question is not what could break a deadlock, but what, if anything, remains of the enterprise behind the ticker.

Company and Latest Development

Core One Labs is a research-and-development company focused on psychedelic medicine, including biosynthetic production of psilocybin and delivery-technology platforms, alongside interests spanning natural health products and medical clinics. Its shares historically traded in Canada on the Canadian Securities Exchange (CSE) and in the U.S. over-the-counter market. The most consequential recent development is a listing failure rather than a clinical one: the company was delisted from the CSE on September 19, 2025, leaving the U.S. OTC Quotation as its principal remaining venue. That transition coincided with an almost total collapse in the equity's value.

What Is Driving Attention Around CLABF?

The "holds steady" framing in the original headline is a data artifact. At a quote near $0.00001, the stock cannot move in normal percentage terms because it is already at the practical floor of quoted prices; a flat reading reflects the absence of a functioning two-sided market, not stability. There is no single verified public catalyst driving fresh interest. Instead, attention around CLABF is characteristic of a delisted nano-cap: sporadic speculative Volume against a backdrop of severe financial distress.

Key Numbers and Company Position

Available market data show CLABF quoted at roughly $0.00001, with a market Capitalization measured in the tens of dollars and a decline of about 99.95% over the trailing year. Aggregated financial data indicate trailing-twelve-month revenue of only a few hundred thousand dollars and a net loss in the range of roughly $12 million, against a modest share count. Those figures underscore a company generating minimal revenue while absorbing losses far larger than its remaining market value. Investors should treat any single data point cautiously given the illiquidity and the delisting.

What Could Come Next?

For a company in this position, the meaningful catalysts are structural rather than clinical: any restructuring, recapitalization, reverse split, financing, asset sale, or corporate reorganization would materially change the picture. Continued OTC trading, the status of prior Loan agreements, and whether the company maintains its regulatory filings are the developments most worth monitoring. Absent a transaction that injects capital or restores a listing, the practical path forward is narrow.

Risks to Watch

The risks are extreme and largely existential. A sub-penny, delisted Equity carries a heightened risk of total loss, with negligible liquidity, wide effective spreads, and limited transparency. Going-concern pressure is implied by losses that dwarf the market value, and further dilution or a corporate wind-down cannot be ruled out. The psychedelics sector itself remains early-stage and highly speculative, compounding company-specific distress.

Conclusion

Core One Labs Inc illustrates how a micro-cap can move from an exchange listing to the fringes of the OTC market in a single year. With CLABF quoted at a fraction of a cent following its September 2025 CSE delisting, the "steady" tape masks a near-total loss of value rather than a balanced market. Investors may be watching for any restructuring, financing, or corporate action, while recognizing that, at current levels, the equity reflects deep distress and the real possibility of a complete loss.